CD274 and non-small cell lung carcinoma: Studies with tumor tissue from patients with NSCLC have shown a relationship between high tumor mutational burden (TMB) and a longer duration of response and survival in patients treated with anti-PD-1 or anti-PD-L1 therapy [171,172,173].